Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI)

American Heart Journal

Volumn 158, Issue 6, 2009, Pages

  Berger, Jeffrey S ^a   Roe, Matthew T ^a   Gibson, C Michael ^b   Kilaru, Rakhi ^a   Green, Cynthia L ^a   Melton, Laura ^a   Blankenship, James D ^c   Metzger, D Christopher ^d   Granger, Christopher B ^a   Gretler, Daniel D ^e   Grines, Cindy L ^f   Huber, Kurt ^g   Zeymer, Uwe ^h   Buszman, Pawel ⁱ   Harrington, Robert A ^a   Armstrong, Paul W ^j  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c GEISINGER MEDICAL CENTER   (United States)

^d Pharmacy Services   (United States)

^e Portola Pharmaceuticals Inc   (United States)

^f WILLIAM BEAUMONT HOSPITAL   (United States)

^g WILHELMINEN HOSPITAL   (Austria)

^h KLINIKUM LUDWIGSHAFEN   (Germany)

ⁱ MEDICAL UNIVERSITY OF SILESIA   (Poland)

^j UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ELINOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO; PURINERGIC P2Y12 RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DISSECTION; ARTICLE; BLEEDING; BLOOD VESSEL INJURY; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; ST SEGMENT ELEVATION; THORAX PAIN; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 70649090353     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.10.010     Document Type: Article

References (17)

1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343 (1994) 311-322
2. Antman E.M., Hand M., Armstrong P.W., et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 117 (2008) 296-329
3. Silber S., Albertsson P., Aviles F.F., et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26 (2005) 804-847
4. Nallamothu B.K., Bradley E.H., and Krumholz H.M. Time to treatment in primary percutaneous coronary intervention. N Engl J Med 357 (2007) 1631-1638
5. Ellis S.G., Tendera M., de Belder M.A., et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358 (2008) 2205-2217
6. Lieu H.D., Conley P.B., Andre P., et al. Initial intravenous experience with PRT060128 (PRT128), an orally-available, direct-acting, and reversible P2Y12 inhibitor. J Thromb Haemost 5 supplement 2 (2007) P-T-292 (abstract)
7. Chesebro J.H., Knatterud G., Roberts R., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76 (1987) 142-154
8. Berkowitz S.D., Granger C.B., Pieper K.S., et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 95 (1997) 2508-2516
9. Stone G.W., Webb J., Cox D.A., et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 293 (2005) 1063-1072
10. Gibson C.M., Kirtane A.J., Murphy S.A., et al. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J 152 (2006) 668-675
11. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
12. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
13. King III S.B., Smith Jr. S.C., Hirshfeld J.W.J.R., et al. Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol 51 (2008) 172-209
14. Quinn M.J., and Fitzgerald D.J. Ticlopidine and clopidogrel. Circulation 100 (1999) 1667-1672
15. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
16. Montalescot G., Wiviott S., Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction in TRITON-TIMI 38. Lancet 373 (2009) 723-731
17. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel for patients with acute coronary syndromes. N Engl J Med 361 (2009) 1045-1057